Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Precigen Inc. (NASDAQ:PGEN) is one of the penny stocks with explosive growth potential. On June 15, Precigen secured FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine treating adult ...

Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On ...

Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason

Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time. Precigen rallied for a second day on Monday, surging ...
AOL

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing. Precigen, Inc.
The Motley Fool

Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?

NASDAQ: TARS: $145.9 million (5.6% of AUM) NASDAQ: GLPG: $143.8 million (5.5% of AUM) NASDAQ: AUPH: $125.2 million (4.8% of AUM) NASDAQ: PTCT: $92.1 million (3.5% of AUM) NASDAQ: MIRM: $90.6 million ...

Precigen Inc

View Precigen Inc PGEN stock quote prices, financial information, real-time forecasts, and company news from CNN.
MM&M

Precigen chief commercial officer: How AI is impacting rare disease marketing

Precigen believes that AI — combined with human interactions — is the future for rare disease marketing. The cell and gene therapy biotech has even tested out its hypothesis in its latest ad campaign.
AOL

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Precigen develops gene and cellular therapies, disease-modifying therapeutics, and proprietary platforms such as UltraVector, Sleeping Beauty, UltraCAR-T, and AdenoVerse Immunotherapy. Operates a ...
FiercePharma

Precigen adds to disease awareness calendar with day dedicated to recurrent respiratory papillomatosis

As it advances its therapeutic vaccine for recurrent respiratory papillomatosis (RRP) through clinical trials, Precigen is also working to raise awareness for the rare disease. The biotech has teamed ...
Nasdaq

Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition

- Case study demonstrated persistence of PRGN-3006 administered without prior lymphodepletion in blood at seven months post-infusion and reduction in blood and bone marrow blasts - - Milestone marks a ...
Nasdaq

Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Precigen, Inc. (PGEN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

This is the only open-market sale by the CFO in the past year, following a long stretch of administrative filings, and leaves him with a direct position valued at ~$2.50 million as of May 28, 2026.